Clinical Trial Update: Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for intranasal glulisine in mild cognitive impairment and probable Alzheimer's disease has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• glulisine (glulisine)

Snippet

Sponsor: HealthPartners Institute | Conditions: Mild Cognitive Impairment, Alzheimer's Disease (AD) | Phase 2 | Status: TERMINATED | Results posted: 2020-04-09